24th week of 2017 patent applcation highlights part 7 |
Patent application number | Title | Published |
20170165155 | METHOD OF TREATING HAIR - A method of treating the hair including providing a concentrated hair care composition in an aerosol foam dispenser. The concentrated hair care composition includes one or more silicones, perfume, an emulsifier system, and less than 10% high melting point fatty compounds. The method also includes dispensing the concentrated hair care composition from the aerosol foam dispenser as a dosage of foam; applying the foam to the hair; and rinsing the foam from the hair. The foam has a density of from about 0.025 g/cm | 2017-06-15 |
20170165156 | METHOD OF TREATING HAIR - A method of treating the hair including providing a concentrated hair care composition in a dispenser. The concentrated hair care composition includes one or more oils, perfume, and from about 2% to about 10% high melting point fatty compounds. The method also includes dispensing the concentrated hair care composition from the dispenser, applying the concentrated hair care composition the hair; and rinsing the concentrated hair care composition from the hair. | 2017-06-15 |
20170165157 | METHOD OF TREATING HAIR - A method of treating the hair including providing a concentrated hair care composition in a dispenser. The concentrated hair care composition includes one or more silicones, perfume, an emulsifier system, and from about 2% to about 10% high melting point fatty compounds. The method also includes dispensing the concentrated hair care composition from the dispenser, applying the concentrated hair care composition the hair; and rinsing the concentrated hair care composition from the hair. | 2017-06-15 |
20170165158 | HAIR TREATMENT COMPOSITION - Disclosed is a hair treatment composition comprising from 0.00001 to 1% zinc salt by weight of the composition, from 0.2 to 2% non-ionic surfactant by weight of the composition, and a preservative system comprising an antimicrobial urea derivative. | 2017-06-15 |
20170165159 | COSMETIC KIT FOR PROTECTING THE SKIN AGAINST UV RAYS - The present invention relates to a method for protecting the skin against UV rays, using two cosmetic compositions for protecting against UV rays, the sun protection indices of which are different from each other, this method consisting in applying to the skin, before or during exposure to sunlight, a first composition having a certain sun protection index, and then in applying, during exposure to sunlight, onto the residual deposit of the first composition, the second cosmetic composition having a sun protection index lower than that of the first composition. | 2017-06-15 |
20170165160 | METHOD OF INCREASING THE WASH RESISTANCE OF ARTIFICIALLY COLORED HAIR - A method of reducing and/or preventing the bleaching and/or fading of artificially produced hair colors, includes the following steps: i. applying a cosmetic composition to the preferably wet, colored hair, ii. allowing the composition to act for a period of at least 5 s, iii. optionally: rinsing the composition out with water. The cosmetic composition, based on the weight thereof, includes a) 0.05 to 0.5 mol/kg of at least one divalent salt of a monobasic organic acid or b) 0.01 to 0.5 mol/kg of at least one monobasic organic acid (b1) and 0.05 to 0.5 mol/kg of at least one divalent inorganic salt (b2), and the cosmetic composition has a pH in the range from 4.0 to 4.8. | 2017-06-15 |
20170165161 | OXIDIZING AGENT FOR THE OXIDATIVE COLORING AND BLONDING TREATMENT OF KERATIN FIBERS HAVING A REDUCED DAMAGING EFFECT - An oxidizing composition for oxidatively coloring or blonding hair is gentle on the hair. A method for oxidatively coloring or blonding hair protects keratin fibers from oxidative influences. | 2017-06-15 |
20170165162 | METHOD OF TREATING HAIR - A method of treating the hair including providing a concentrated hair care composition in a mechanical foam dispenser. The concentrated hair care composition includes one or more oils, from about 1% to about 5% perfume, and has 0% high melting point fatty compounds. The method also includes dispensing the concentrated hair care composition from the mechanical foam dispenser as a dosage of foam; applying the foam to the hair; and rinsing the foam from the hair. The foam has a density of from about 0.025 g/cm | 2017-06-15 |
20170165163 | METHOD OF TREATING HAIR - A method of treating the hair including providing a concentrated hair care composition in an aerosol foam dispenser. The concentrated hair care composition includes from about 3% to about 18% of one or more oils, perfume, and less than 8% high melting point fatty compounds. The method also includes dispensing the concentrated hair care composition from the aerosol foam dispenser as a dosage of foam; applying the foam to the hair; and rinsing the foam from the hair. The foam has a density of from about 0.025 g/cm | 2017-06-15 |
20170165164 | DEEP CLEANSING HAIR CARE COMPOSITION - A shampoo composition is disclosed that has from about 5 to about 40 weight % of one or more detersive surfactants and an aqueous carrier comprising water and one or more polyols, wherein the weight ratio of one or more polyols to water is higher than or equal to about 0.4, and the water content is higher than or equal to about 9% by weight of the composition. The composition delivers thorough hair cleansing, good lather, good conditioning wet feel, clean rinse feel during use, leaving hair with very low residue on the hair surface. The use of the shampoo composition also provides high hair volume, smooth dry hair feel, and bouncy hair that is easy to style. | 2017-06-15 |
20170165165 | DEEP CLEANSING HAIR CARE COMPOSITION - A shampoo composition is disclosed that has from about 5 to about 40 weight % of one or more detersive surfactants and an aqueous carrier comprising water and one or more polyols, wherein the weight ratio of one or more polyols to water is higher than or equal to about 0.4, and the water content is higher than or equal to about 9% by weight of the composition. The composition delivers thorough hair cleansing, good lather, good conditioning wet feel, clean rinse feel during use, leaving hair with very low residue on the hair surface. The use of the shampoo composition also provides high hair volume, smooth dry hair feel, and bouncy hair that is easy to style. | 2017-06-15 |
20170165166 | SUBSTITUTED P-PHENYLENEDIAMINES AS NEW OXIDATION DYE PRECURSOR PRODUCTS OF THE DEVELOPER TYPE - Compounds, and agents for oxidatively changing the color of keratinic fibers that include such compounds, in particular human hair, in a cosmetic carrier. The compounds are at least one oxidation dye precursor product of formula (I) and/or physiologically acceptable salt thereof, | 2017-06-15 |
20170165167 | SURFACTANT-CONTAINING CLEANING AGENT COMPOSITIONS WITH SPECIFIC PRESERVATIVE COMBINATIONS - Cleaning compositions include at least one specific preservative combination. The cleaning compositions are used for cleaning and/or caring for the skin and/or hair, and the specific preservative combination is used for the preservation of surfactant-containing cleaning compositions. | 2017-06-15 |
20170165168 | EMULSIONS INCLUDING AT LEAST ONE SPECIAL PRESERVATIVE COMBINATION - Cosmetic agents in the form of emulsions include synergistically effective preservative combinations. The cosmetic agents are used to cleanse and/or nurture skin and/or hair. | 2017-06-15 |
20170165169 | SURFACTANT-CONTAINING CLEANSING AGENTS WITH AT LEAST THREE DIFFERENT PRESERVATIVES - Cleansing compositions include at least one special preservative combination. The cleansing compositions are used for the cleaning and/or care of skin and/or hair, and specific preservative combination is used for preserving such surfactant-containing cleansing compositions. | 2017-06-15 |
20170165170 | EMULSIONS COMPRISING AT LEAST THREE DIFFERENT PRESERVATIVES - Cosmetic agents in the form of emulsions include synergistically effective preservative combinations. The cosmetic agents according to the present invention are used to clean and/or care for skin and/or hair. | 2017-06-15 |
20170165171 | PRODUCT AND METHOD FOR TEMPORARY SHAPING OF KERATIN-CONTAINING FIBERS - Cosmetic products and methods for temporarily shaping keratin-containing fibers using the cosmetic products are provided herein. A cosmetic product for temporarily shaping keratinic fibers includes a cosmetic preparation. The cosmetic preparation contains at least one copolymer a1) that is constructed from at least the following monomer units: (meth)acrylic acid, (meth)acrylic acid alkyl ester, and (meth)acrylic acid hydroxy alkyl ester. The cosmetic preparation further contains at least one copolymer a2) that is constructed from at least the following monomer units: styrene, and at least one of acrylic acid or methacrylic acid. The proportion by weight of copolymers a1) and a2) with respect to the total weight of the cosmetic preparation is about 1.0 to about 10 wt %. | 2017-06-15 |
20170165172 | AGENT AND METHOD FOR TEMPORARILY DEFORMING KERATIN-CONTAINING FIBERS - Cosmetic agents for temporarily deforming keratinic fibers and methods for temporarily deforming keratinic fibers using the cosmetic agents are provided. In an embodiment, a cosmetic agent comprises:
| 2017-06-15 |
20170165173 | Hair Coloring Composition Comprising One or More Acrylic Compounds - A hair coloring composition is provided and includes, in a cosmetically acceptable carrier: one or more acrylic compounds of Formula I, or a cosmetically acceptable salt thereof, or a mixture thereof: | 2017-06-15 |
20170165174 | Hair Coloring Composition Comprising One or More Acrylate Monomers - A hair coloring composition is provided and includes, in a cosmetically acceptable carrier, one or more acrylate monomers. The one or more acrylate monomers have the general Formula I: | 2017-06-15 |
20170165175 | COSMETIC COMPOSITION FOR TEMPORARY RESHAPING OF KERATINIC FIBERS - The present invention relates to a cosmetic composition for the temporary shaping of hair, which includes a combination of two specific anionic acrylate resins. The cosmetic composition provides a very good combination of stiffness and long-lasting hold. | 2017-06-15 |
20170165176 | AGENT AND METHOD FOR TEMPORARY SHAPING OF KERATIN-CONTAINING FIBERS - Cosmetic agents and methods for temporary shaping of keratinic fibers using the cosmetic agents are provided herein. In one embodiment, a cosmetic agent for temporary shaping of keratinic fibers includes a cosmetic preparation. The cosmetic preparation contains at least one copolymer a1) composed of at least the following monomer units: N-tert-octylacrylamide, acrylic acid, and tert-butylaminoethyl methacrylate. The cosmetic preparation further contains at least one copolymer a2) composed of at least the following monomer units: N-tert-butylacrylamide, acrylic acid, and ethyl acrylate. The amount by weight of copolymers a1) and a2) in the total weight of the cosmetic preparation amounts to about 1.0 to about 10 by weight. | 2017-06-15 |
20170165177 | AGENT AND METHOD FOR TEMPORARY SHAPING OF KERATIN-CONTAINING FIBERS - Cosmetic agents and methods for temporarily shaping keratin-containing fibers using the cosmetic agents are provided herein. In one embodiment, a cosmetic agent for temporarily shaping keratinic fibers includes a cosmetic preparation. The cosmetic preparation contains at least one copolymer a1) composed of at least the following monomer units: (meth)acrylic acid, (meth)acrylic acid alkyl ester, and (meth)acrylic acid hydroxyalkyl ester. The cosmetic preparation further contains at least one copolymer a2) composed of at least the following monomer units: N-tert-octylacrylamide, acrylic acid, and ethyl acrylate. The amount by weight of copolymers a1) and a2) in the total weight of the cosmetic preparation amounts to about 1.0 to about 10 by weight. | 2017-06-15 |
20170165178 | PRODUCT AND METHOD FOR TEMPORARY SHAPING OF KERATIN-CONTAINING FIBERS - Cosmetic products and methods for temporarily shaping keratinic fibers using the cosmetic products are provided herein. A cosmetic product for temporarily shaping keratinic fibers includes a cosmetic preparation. The cosmetic preparation contains at least one copolymer a1) that is constructed from at least the following monomer units: N-tert-octylacrylamide, acrylic acid, and tert.-butylaminoethyl methacrylate. The cosmetic preparation further contains at least one copolymer a2) that is constructed from at least the following monomer units: styrene, and at least one of acrylic acid or methacrylic acid. The proportion by weight of copolymers a1) and a2) with respect to the total weight of the cosmetic preparation is about 10 to about 30 wt %. | 2017-06-15 |
20170165179 | AGENTS AND METHOD FOR THE TEMPORARY SHAPING OF KERATIN-CONTAINING FIBERS - Cosmetic agents and methods for the temporary shaping of keratinic fibers using the cosmetic agents are provided herein. In one embodiment, the cosmetic agent for the temporary shaping of keratinic fibers includes a cosmetic preparation. The cosmetic preparation contains at least one copolymer a1), made up of at least the following monomer units: N-tert-octylacrylamide, acrylic acid, and tert-butylaminoethyl methacrylate. The cosmetic preparation further contains at least one copolymer a2), made up of at least the following monomer units: styrene, and at least one of acrylic acid or methacrylic acid. The weight proportion of copolymers a1) and a2) in terms of the total weight of the cosmetic preparation is about 1.0 to about 10% by weight. | 2017-06-15 |
20170165180 | AGENT AND METHOD FOR THE TEMPORARY DEFORMATION OF KERATIN-CONTAINING FIBERS - A cosmetic agent for the temporary deformation of keratinous fibers and a method for the temporary deformation of keratinous fibers using the cosmetic agent are provided. The cosmetic agent comprises:
| 2017-06-15 |
20170165181 | AGENT AND METHOD FOR THE TEMPORARY SHAPING OF KERATIN FIBERS - Cosmetic agents and methods for the temporary shaping of keratinic fibers using the cosmetic agents are provided herein. In one embodiment, the cosmetic agent for the temporary shaping of keratin fibers includes a cosmetic preparation. The cosmetic preparation contains at least one copolymer a1) which is composed at least of the following monomer units: N-tert-octylacrylamide, acrylic acid, and tert-butylaminoethyl methacrylate. The cosmetic preparation further contains at least one copolymer a2) which is composed at least of the following monomer units: (meth)acrylic acid, (meth)acrylic acid alkyl ester, and (meth)acrylic acid hydroxyalkyl ester. The proportion by weight of the copolymers a1) and a2) based on the total weight of the cosmetic preparation is about 1.0 to about 10% by weight. | 2017-06-15 |
20170165182 | AGENT AND METHOD FOR TEMPORARILY DEFORMING KERATIN-CONTAINING FIBERS - Cosmetic agents and methods for temporarily deforming keratinic fibers using the cosmetic agents are provided herein. In one embodiment, the cosmetic agent includes a cosmetic preparation. The cosmetic preparation contains at least one copolymer a1) constructed at least from the following monomer units: N-tert-octylacrylamide, acrylic acid, and tert-butylaminoethyl methacrylate. The cosmetic preparation further contains at least one copolymer a2) constructed at least from the following monomer units: N-tert-butylacrylamide, acrylic acid, and ethyl acrylate. The proportion by weight of copolymers a1) and a2) in the total weight of the cosmetic preparation is about 10 to about 30% by weight. | 2017-06-15 |
20170165183 | AGENT AND METHOD FOR THE TEMPORARY DEFORMATION OF KERATIN-CONTAINING FIBERS - Cosmetic agents and methods for the temporary deformation of keratinous fibers using the cosmetic agents are provided herein. In one embodiment, the cosmetic agent for the temporary deformation of keratinous fibe includes a cosmetic preparation. The cosmetic preparation contains at least one copolymer a1) composed at least of the following monomer units: styrene, and at least one of acrylic acid or methacrylic acid. The cosmetic preparation further contains at least one copolymer a2) composed at least of the following monomer units: N-tert-butylacrylamide, acrylic acid, and ethyl acrylate. The weight fraction of copolymers a1) and a2) in the total weight of the cosmetic preparation is about 10 to about 30% by weight. | 2017-06-15 |
20170165184 | AGENT AND METHOD FOR THE TEMPORARY SHAPING OF KERATIN-CONTAINING FIBERS - Cosmetic agents and methods for the temporary deformation of keratin-containing fibers using the cosmetic agents are provided herein. In one embodiment, the cosmetic agent for the temporary shaping of keratinic fibers includes a cosmetic preparation. The cosmetic preparation includes at least one copolymer a1), made up of at least the following monomer units: (meth)acrylic acid, (meth)acrylic acid alkyl ester, and (meth)acrylic acid hydroxyalkyl ester. The cosmetic preparation further includes at least one copolymer a2), made up of at least the following monomer units: N-tert-butylacrylamide, acrylic acid, and ethyl acrylate. The weight proportion of copolymers a1) and a2) in terms of the total weight of the cosmetic preparation is about 10 to about 30% by weight. | 2017-06-15 |
20170165185 | AGENT AND METHOD FOR THE TEMPORARY SHAPING OF KERATIN-CONTAINING FIBERS - Cosmetic agents and methods for the temporary deformation of keratin-containing fibers using the cosmetic agents are provided herein. In one embodiment, the cosmetic agent for the temporary shaping of keratinic fibers includes a cosmetic preparation. The cosmetic preparation includes at least one copolymer a1), made up of at least the following monomer units: N-tert-octylacrylamide, acrylic acid, and tert-butylaminoethyl methacrylate. The cosmetic preparation further includes at least one copolymer a2), made up of at least the following monomer units: (meth)acrylic acid, (meth)acrylic acid alkyl ester, and (meth)acrylic acid hydroxyalkyl ester. The weight proportion of copolymers a1) and a2) in terms of the total weight of the cosmetic preparation is about 10 to about 30% by weight. | 2017-06-15 |
20170165186 | COSMETIC COMPOSITION FOR TEMPORARY RESHAPING OF KERATINIC FIBERS - The invention relates to a cosmetic composition for the temporary shaping of hair, including a combination of the two specific (co)polymers. Said cosmetic preparation provides an extremely good combination of stiffness and long-term hold. | 2017-06-15 |
20170165187 | OIL-IN -WATER EMULSION SUNSCREEN COMPOSITION - In accordance with the present invention there is provided an oil-in-water emulsion sunscreen composition comprising (a) a UV active, (b) a first emulsifier having an HLB value less than 5 and (c) optionally a second emulsifier having an HLB value greater than 5 present in an amount of less than 0.2% w/w of the composition. The oil-in-water sunscreen composition is characterized by the absence of an emulsifiable polymer and is capable of providing little to no whitening when applied to wet skin. | 2017-06-15 |
20170165188 | HAIR CONDITIONING COMPOSITIONS - Abstract The use of a water soluble ester of formula RCOXR′ as a hair conditioning agent, wherein R is an optionally | 2017-06-15 |
20170165189 | ORAL AND DENTAL CARE AND CLEANING AGENTS COMPRISING PHOSPHATE-CONTAINING AND/OR PHOSPHONATE-CONTAINING POLYURETHANE POLYMERS - The present invention relates to oral and dental care and cleaning agents comprising an aqueous dispersion of a phosphate-containing and/or phosphonate-containing polyurethane polymer and anionic surfactant(s), to tooth cleaning methods using these agents, and to the use of oral and dental care and cleaning agents comprising an aqueous dispersion of a phosphate-containing and/or phosphonate-containing polyurethane polymer and anionic surfactant(s) to reduce the restaining of teeth and/or to reduce biofilm development on dental surfaces and/or to reduce the adhesion of bacteria to dental surfaces and/or to extend the antibacterial action of antibacterial substances. | 2017-06-15 |
20170165190 | PITUITOUS SILICONE FLUID - A pituitous silicone fluid includes a hydrosilylation reaction product and a carrier fluid. The hydrosilylation reaction product is the reaction product of a first linear organopolysiloxane and a second linear organopolysiloxane. The first linear organo-polysiloxane includes (R | 2017-06-15 |
20170165191 | METHOD OF TREATING HAIR - A method of treating the hair including providing a concentrated hair care composition in a mechanical foam dispenser. The concentrated hair care composition includes one or more silicones, from about 1% to about 5% perfume, an emulsifier system, and is substantially free of high melting point fatty compounds. The method also includes dispensing the concentrated hair care composition from the mechanical foam dispenser as a dosage of foam; applying the foam to the hair; and rinsing the foam from the hair. The foam has a density of from about 0.025 g/cm | 2017-06-15 |
20170165192 | Oral Care Compositions and Methods - An oral care composition and methods for making and using same are provided. In at least one embodiment, the oral care composition can include ethylcellulose, a binder, a plasticizer, a fluoride compound, a solvent, and fumed silica. In another embodiment, the oral care composition can include ethylcellulose, hydrogenated rosin, and acetyl tributyl citrate. | 2017-06-15 |
20170165193 | TOPICAL SKIN CARE FORMULATIONS COMPRISING PLANT EXTRACTS - Disclosed are methods of treating skin with topical skin compositions comprising at least one plant extract. | 2017-06-15 |
20170165194 | COSMETIC AND FACIAL REGENERATION COMPOSITION DERIVED FROM POTENTIATED ADIPOSE DERIVED CELLS AND SUPERNATANTS THEREOF - This patent discloses new data supporting superior collagen induction by cosmetically useful preparations derived from adipose stem cells that have been manipulated for superior growth factor and anti-aging properties. In one embodiment cellular mixtures derived from adipose tissue are composed, induced to produce regenerative factors, with said regenerative factors harvested and compounded into cosmetic preparations. In one embodiment, the invention provides for manufacture of adipose derived regenerative factor (ARDF), which may be utilized as a cosmetic and skin rejuvenating agent. | 2017-06-15 |
20170165195 | EDIBLE CRICKET COMPOSITION FOR PREVENTING HAIR LOSS, IMPROVING HAIR FOLLICLE, AND PROMOTING HAIR REGROWTH - A hair regrowth is developed using edible crickets. The edible crickets are provided in the form of 60-100 g of powders or in the form of 60-100 g of formulations on a daily basis. The edible crickets reduce the concern about side effects and are safe. The intake rate of the edible crickets is higher than those of synthetic medicine of promoting hair regrowth and medicine of preventing hair loss, so that the edible crickets are used for pharmaceuticals, supplements, and cosmetics. The edible crickets contains iron (Fe), zinc (Ze), copper (Cu), and biotin (Biotin, Vitamin B7) higher than nutritional ingredients contained in vitamins sold on the market in content, and a large amount of amino acids constituting hairs, so that an excellent effect is produced on hair regrowth. The promotion of hair regrowth, the prevention of hair loss, and the improvement of hair follicles are easily recognized. | 2017-06-15 |
20170165196 | Cosmetic Cream Formulation - A cosmetic cream formulation for cleaning, restoring, replenishing, and moisturizing a user's skin is provided. The cosmetic cream formulation comprises a cosmetic cream having one part pumpkin and one part honey. The cosmetic cream revitalizes the user's skin to a more healthy and youthful feeling, tone and appearance. | 2017-06-15 |
20170165197 | DERMATOLOGICAL STICK COMPRISING PLANT EXTRACTS, METHODS AND USES THEREOF - The present invention relates to dermatological stick compositions containing natural emollient waxes, oils and as active ingredient plants extract, and to uses thereof, in particular in the treatment dermatological disorders, such as lichen scleroses. | 2017-06-15 |
20170165198 | LIPOSOME COMPRISING ELASTIN-LIKE POLYPEPTIDE AND TUMOR CELL TARGETING MATERIAL AND USE THEREOF - A liposome including an elastin-like polypeptide (ELP) and a tumor cell targeting material, a pharmaceutical composition including the liposome, and a method of delivering an active agent to a target site using the liposome. | 2017-06-15 |
20170165199 | DRIED FORMULATIONS OF NANOPARTICLE-COATED CAPSULES - A method of producing a dried formulation for an active substance such as a drug compound is described. The method involves dispersing a discontinuous phase (e.g. an oil-based or lipidic medium) comprising the active substance into a continuous phase (e.g. water) so as to form a two-phase liquid system comprising droplets of said discontinuous phase, allowing nanoparticles to congregate at the phase interface at the surface of the droplets such that at least one layer of nanoparticles coat the droplets and thereby provide sufficient structural integrity to the droplets to enable the subsequent removal of the continuous phase, and thereafter removing the continuous phase from the nanoparticle-coated droplets to produce a dried formulation. | 2017-06-15 |
20170165200 | COMPOSITION OF LIPID-BASED NANOPARTICLES FOR SMALL MOLECULES AND MACROMOLECULES - Described herein are nanoparticles comprising a mixture of a steroid, a phospholipid composition, an α-tocopheryl compound, and a therapeutic agent wherein the α-tocopheryl compound is presented on the surface of the nanoparticle. In some embodiments, the nanoparticles are useful for delivering a peptide or a protein. In some embodiments, the nanoparticles are formulated for ocular administration. In other embodiments, the nanoparticles are formulated to cross the blood brain barrier for the delivery of the therapeutic agents to the brain. | 2017-06-15 |
20170165201 | PH-RESPONSIVE MUCOADHESIVE POLYMERIC ENCAPSULATED MICROORGANISMS - Methods of encapsulating microorganisms, or components thereof, for targeted enteric delivery to an animal host have been developed. In particular, the encapsulation provides a prolonged survival, extended retention and a pH-sensitive release of the encapsulated microorganisms or antigenic components thereof at targeted sites within the gastrointestinal tract. The formulations are useful for diagnostic, therapeutic and prophylactic purposes and can alter a host's microbial composition associated with a condition or a disease state. | 2017-06-15 |
20170165202 | COMPOSITION FOR TRANSARTERIAL CHEMOEMBOLIZATION, COMPRISING FIRST AND SECOND BIODEGRADABLE MICROBEADS, AND PREPARATION METHOD THEREFOR - The present invention provides: a composition for transarterial chemoembolization, comprising two types of biodegradable microbeads having different anticancer drug release characteristics; and a preparation method therefor. According to the present invention, a composition for transarterial chemoembolization exhibiting a desired anticancer drug release characteristic can be effectively prepared by controlling the mixing ratio of first and second biodegradable microbeads. Therefore, the present invention can be usefully applied to the transarterial chemoembolization of liver cancer. | 2017-06-15 |
20170165203 | Method for the Production of Commercial Nanoparticle and Microparticle Powders - The present invention relates to methods for producing nanoparticle and microparticle powders of a biologically active material which have improved powder handling properties making the powders suitable for commercial use using dry milling processes as well as compositions comprising such materials, medicaments produced using said biologically active materials in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of said biologically active materials administered by way of said medicaments. | 2017-06-15 |
20170165204 | SUSTAINED-RELEASE COMPOSITION AND METHOD FOR PRODUCING THE SAME - Sustained-release compositions wherein a water-soluble physiologically active peptide is substantially uniformly dispersed in a microcapsule comprised of a lactic acid polymer or a salt thereof, and the physiologically active substance is contained in an amount of 15 to 35 wt/wt % to the total microcapsules and weight-average molecular weight (Mw) of the lactic acid polymer is about 11,000 to about 27,000, which is characterized by having a high content of the physiologically active substance, and suppression of the initial excessive release within one day after the administration and a stable drug sustained-release over a long period of time, and method for producing the same. | 2017-06-15 |
20170165205 | ACRYLIC POLYMERS AND THEIR USE IN TRANSDERMAL DRUG DELIVERY - The present disclosure is directed to random, acrylic co-polymers that are useful in transdermal applications. Methods of making and using the described co-polymers are also described. | 2017-06-15 |
20170165206 | EPINEPHRINE FORMULATIONS - Pharmaceutical compositions comprising epinephrine, methods of administration, and methods of making the same. Compositions may comprise at least one of an active agent, a pH raising agent, an antioxidant, a transition metal complexing agent, a pH lowering agent, a tonicity regulating agent, optionally a preservative, and optionally a solvent. | 2017-06-15 |
20170165207 | CYSTEAMINE IN THE TREATMENT OF FIBROTIC DISEASE - Fibrotic diseases are characterized by the replacement of healthy tissue with scar tissue and extracellular matrix in response to tissue damage. Here we describe the reduction of extracellular matrix (ECM) deposition, interstitial fibroblasts, interstitial volume, expression of Collagen I mRNA and protein, expression of profibrotic cytokines and macrophage infiltration by Cysteamine treatment. | 2017-06-15 |
20170165208 | ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THEIR USE - Topical and wash compositions comprising a polymeric biguanide or a bis(biguanide) compound, a chelating agent and a buffering agent and methods for using these compositions for the prevention or treatment of skin or ear tissue infections is provided. | 2017-06-15 |
20170165209 | Compositions Comprising Statins, Biguanides and Further Agents for Reducing Cardiometabolic Risk - Compositions and methods comprising at least one biguanide compound and at least one statin combined with at least one additional active agent in fixed dose combinations are provided for reducing cardiometabolic risk, and for the treatment of cardiovascular disease, wherein the biguanide compound is formulated for delayed release. | 2017-06-15 |
20170165210 | Pharmaceutical Compositions Comprising Paracetamol and Process for Preparing The Same - Disclosed herein are injectable compositions containing high concentration of paracetamol or its pharmaceutically acceptable salts wherein the concentration of paracetamol or its pharmaceutically acceptable salt is >150 mg/ml in a judiciously tailored solvent system comprising glycofurol, ethanol, water or a solvent system comprising glycofurol, ethanol, polyethylene glycol, water. The viscosity of the said injectables is <28 cps. Further disclosed is the process for preparing the said injectables. The injectables can be administered by intramuscular route, intravenous route or as intravenous infusion after diluting in one of the routinely used intravenous fluids, infusion solutions of antibacterial, antifungal and amoebicidal drugs and along with anxiolytics (Midazolam injection) or narcotic analgesics (Fentanyl Citrate injection etc) as they remain stable, clear and transparent at least for 6 hours after dilution. | 2017-06-15 |
20170165211 | MODIFIED TAURINE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASES CONTAINING SAME - The present invention relates to a modified taurine, and a pharmaceutical composition for preventing or treating metabolic disease or a food composition, which contains the modified taurine as an active ingredient. More specifically, the modified taurine of the present invention has physical properties different from those of existing taurine, and has significant effects on the prevention and treatment of metabolic syndrome, including antithrombotic effects. | 2017-06-15 |
20170165212 | TRANSDERMAL ADMINISTRATION OF TAMSULOSIN - In an aspect of the invention, a composition for making a patch for the transdermal delivery of tamsulosin is provided. The composition comprises (a) at least about 1 wt % tamsulosin or a pharmaceutically acceptable salt of tamsulosin, (b) at least about 40 wt % polyisobutylene adhesive or hydrophobic synthetic rubber adhesive, (c) about 1-20 wt % of an aprotic solvent in which tamsulosin dissolves readily, (d) about 1-20 wt % of an unsaturated fatty acid or an alpha-hydroxy acid or a mixture of unsaturated fatty acids or alpha-hydroxy acids or of both unsaturated fatty acids and alpha-hydroxy acids, (e) a lipophilic permeation enhancer, and (f) a matrix modifier. | 2017-06-15 |
20170165213 | SCFA COLONIC COMPOSITION - The present invention is directed to a colonic composition including a core having at least one short chain fatty acid selected from the group consisting of butyrate, acetate and propionate, and combinations thereof, or a pharmaceutically acceptable salt or ester thereof; wherein at least one of acetate or propionate is present in the core; and at least one digestion-resistant layer covering the core, the digestion-resistant layer disintegrating in the colon. The present invention is also directed to methods of treatment using the above composition. | 2017-06-15 |
20170165214 | SCFA COLONIC COMPOSITION - The present invention is directed to a colonic composition including a core having at least one short chain fatty acid selected from the group consisting of butyrate, acetate and propionate, and combinations thereof, or a pharmaceutically acceptable salt or ester thereof; wherein at least one of acetate or propionate is present in the core; and at least one digestion-resistant layer covering the core, the digestion-resistant layer disintegrating in the colon. The present invention is also directed to methods of treatment using the above composition. | 2017-06-15 |
20170165215 | System and Method for Delivering Protease Inhibitors - The disclosed invention provides a system and method of artificially retarding fibrin-based blood clot degradation via the sustained release of a protease inhibitor, such as, for example, aprotinin or tranexamic acid (“TA”). The sustained release of the protease inhibitor is accomplished through incorporation within a biodegradable polymer microsphere to produce a protease inhibitor formulation. Next, the formulation along with fibrinogen and thrombin is applied to a wound site where an outer surface of the polymer microsphere degrades in a proteolytic environment to expose and release the incorporated protease inhibitor to the surrounding hydrogel or sealant or clot matrix at the wound site. | 2017-06-15 |
20170165216 | Methods and Compositions for Treatment of Acute Lung Injury - A method of treating acute lung injury (ALI) in a patient suspected of having ALI is disclosed. The method includes administering to the patient a therapeutically effective amount of an inducible nitric oxide synthase (iNOS) inhibitor. | 2017-06-15 |
20170165217 | LIQUID DOSAGE FORMS OF ISOTRETINOIN - The present invention relates to a pharmaceutical solution comprising isotretinoin or salts thereof. The present invention further relates to the processes for preparing such compositions. | 2017-06-15 |
20170165218 | LOW DOSE ORAL PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN - The present invention provides a low dose oral pharmaceutical composition of isotretinoin having reduced food effect, in particular no food effect. The present invention further relates to a process for preparing the oral pharmaceutical composition of the present invention. | 2017-06-15 |
20170165219 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS - Compounds of formula (I), wherein R | 2017-06-15 |
20170165220 | TOPICAL PHARMACEUTICAL FORMULATIONS CONTAINING A LOW CONCENTRATION OF BENZOYL PEROXIDE IN SUSPENSION IN WATER AND A WATER-MISCIBLE ORGANIC SOLVENT - An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea. | 2017-06-15 |
20170165221 | Drugs for Treating Diseases of Cervical and/or Lumbar Vertebrae - The present invention relates to a benzbromarone or different pharmaceutically acceptable crystals thereof, or pharmaceutically acceptable solvates, salts, esters, ethers or clathrates thereof, or use of a pharmaceutical composition comprising any of the above in preparation of drugs, application thereof being for preparation of drugs for treating and preventing vertebrae cervicales diseases or lumbar disk herniation (LDH) in human. | 2017-06-15 |
20170165222 | METHOD OF TREATMENT - Embodiments of the invention relate generally to increasing adult height in individuals with no light perception (NLP). | 2017-06-15 |
20170165223 | 3' Equatorial-Fluorine-Substituted Neuraminidase Inhibitor Compounds, Compositions and Methods for the Use Thereof as Anti-Virals - Equatorial 2,3-fluorinated glycosides compounds of formula (I) useful for the treatment or prophylaxis of viral infection, particularly viral influenza, the methods for their preparation, and their pharmaceutical compositions. The therapeutic effect is achieved via inhibition of viral neuraminidases. | 2017-06-15 |
20170165224 | COMPOSITIONS FOR IMPROVING SAFETY OF PHARMACOLOGICAL FORMULATIONS - Disclosed are compositions for improving the safety of pharmaceutical formulations. These compositions include additives for limiting the bioavailability of the active ingredient of a pharmaceutical composition when administered to a subject in a manner other than originally intended. | 2017-06-15 |
20170165225 | Heterocyclic Flavone Derivatives, Compositions, and Methods Related Thereto - In certain embodiments, the disclosure relates to heterocyclic flavone derivatives, such as those described by formula provided herein, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing diseases or conditions related to BDNF and TrkB activity, such as depression, stroke, Rett syndrome, Parkinson's disease, and Alzheimer's disease by administering effective amounts of pharmaceutical compositions comprising compounds disclosed herein. | 2017-06-15 |
20170165226 | COMPOSITION COMPRISING AN ESTER OF ALPHA-TOCOPHEROL FOR PREVENTION AND TREATMENT OF ALLERGIC RHINITIS - Disclosed is a composition for topical application, for use in the prevention and treatment of allergic rhinitis It consists of an ester of alpha-tocopherol selected from the group consisting of tocopheryl acetate, n-propionate and linoleate, and an oily vehicle selected from the group consisting of hydrogenated polyisobutene, hydrogenated polydecene and mixtures of hydrogenated polyisobutene and/or hydrogenated polydecene with hydrogenated polyolefins, in particular hydrogenated C | 2017-06-15 |
20170165227 | POST NERVE INJURY REHABILITATION EFFECT-ENHANCING AGENT COMPRISING ALKYL ETHER DERIVATIVE OR SALT THEREOF - Provided is a medicinal composition characterized by comprising an alkyl ether derivative represented by general formula [1] | 2017-06-15 |
20170165228 | METHODS AND COMPOSITIONS EMPLOYING BICIFADINE FOR TREATING DISABILITY OR FUNCTIONAL IMPAIRMENT ASSOCIATED WITH ACUTE PAIN, CHRONIC PAIN, OR NEUROPATHIC DISORDERS - Methods and compositions are provided for formulating and administering bicifadine and related compounds to treat or prevent functional impairment and disabilities associated with acute pain, chronic pain, and neuropathic disorders. | 2017-06-15 |
20170165229 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS - Compounds of the general structural formula (I) and (II) and use of the compounds and salts and hydrates thereof, as therapeutic agents are disclosed. Treatable diseases and conditions include cancers, inflammatory diseases and conditions, and immunodeficiency diseases. (I), (II). | 2017-06-15 |
20170165230 | USE OF GSK-3 INHIBITORS OR ACTIVATORS WHICH MODULATE PD-1 OR T-BET EXPRESSION TO MODULATE T CELL IMMUNITY - The present application generally relates to the discovery that glycogen synthase kinase 3 (GSK-3) is an upstream signalling molecule that controls PD-1 transcription and Tbet expression by immune cells and in particular T-cells. Based on this discovery, and in view of the known immunosuppressive effect of PD-1 on immunity and the promoting effect of Tbet on T cell immunity, the present invention relates to the use of GSK-3 inhibitors to promote immunity, including cytotoxic T cell immunity in subjects in need thereof, especially subjects with chronic conditions wherein inhibiting PD-1 expression and/or blockade or Tbet up-regulation is therapeutically desirable such as cancer and infectious conditions. Further, based on this discovery the present invention relates to the use of compounds which promote GSK-3 expression or activity to suppress immunity, especially aberrant T cell immunity in subjects in need thereof, e.g., subjects with chronic conditions wherein PD-1 upregulation or Tbet down regulation is therapeutically desirable such as allergic, autoimmune or inflammatory conditions. Also, screening methods for identifying immune agonists and antagonists, especially antibodies, are provided. | 2017-06-15 |
20170165231 | TREATING EWING'S SARCOMA AND EWS-FLI1 RELATED DISORDERS - The field relates to compositions and methods for treating Ewing's Sarcoma and other disorders related to EWS-FLI1. | 2017-06-15 |
20170165232 | THREE-PHASE CONTROLLED-RELEASE TABLET COMPRISING MELATONIN AND PROCESS OF PREPARATION - The invention relates, in one aspect, to a tablet having an internal core and external coating, both comprising melatonin and separated by an internal coating which does not comprise melatonin. The tablet is useful as a medicinal product, dietetic or food supplements for the treatment or as adjunctive therapy in sleep disorders. | 2017-06-15 |
20170165233 | ANTIMICROBIAL DRUG SYNTHESIS AND THERAPEUTIC COMPOSITIONS - This invention relates to the medical use of an antimicrobial agent, racemic Ornidazole, its (R) and (S) enantiomers, or pharmaceutically acceptable salts or esters thereof, and to methods of treatment which involve treating a subject with Ornidazole. The racemic (rac)-ornidazole, its enantiomers, or pharmaceutically acceptable salts or esters thereof, may be used in combination with other actives. The invention also relates to pharmaceutical formulations and compositions comprising (rac)-ornidazole, (R)-ornidazole, (S)-ornidazole, or pharmaceutically acceptable salts or esters thereof, and/or other actives as well as methods to stereoselectively manufacture the enantiomers. | 2017-06-15 |
20170165234 | GPR142 Agonist Compounds - The present invention provides compounds of the Formula (Ia) wherein R is selected from the group consisting of CH | 2017-06-15 |
20170165235 | DEXMEDETOMIDINE PREMIX FORMULATION - The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation. | 2017-06-15 |
20170165236 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND COMBINATION THERAPY THEREWITH - Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided, including compounds which modulate subtype 1 of the S1P receptor, and methods of their therapeutic and/or prophylactic use in combination with at least one other medicament adapted for treatment of a malcondition for which activation of S1P | 2017-06-15 |
20170165237 | COMPLEXES OF SIROLIMUS AND ITS DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The invention is directed to a stable complex with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound Sirolimus or derivatives thereof, which is useful in the prophylaxis of organ rejection in patients receiving renal transplants, in the treatment of psoriasis, facial angiofibromas associated with tuberous sclerosis, fibrofolliculomas found in Birt-Hogg-Dubé Syndrome, chronic erosive oral lichen planus, Early Stage Cutaneous T-cell Lymphoma, Treatment of Autoimmune Active Anterior Uveitis, dry eye syndrome, age-related macular degeneration, diabetic macular edema, noninfectious uveitis, telangiectasia, inflammatory skin diseases (dermatitis, including psoriasis and lichen ruber planus), Pachyonychia Congenita and in the suppression of angiogenesis pathways. More specifically, the complex of the present invention possesses increased apparent solubility, permeability and enhanced biological performance including significantly improved exposure, earlier tmax, higher Cmax and higher trough concentrations at 24 hours which will allow the reduction of the dose. | 2017-06-15 |
20170165238 | ENHANCED DELIVERY OF IMMUNOSUPPRESSIVE DRUG COMPOSITIONS FOR PULMONARY DELIVERY - The present invention includes compositions and methods for making and using a rapid dissolving, high potency, substantially amorphous nanostructured aggregate for pulmonary delivery of tacrolimus and a stabilizer matrix comprising, optionally, a polymeric or non-polymeric surfactant, a polymeric or non-polymeric saccharide or both, wherein the aggregate comprises a surface area greater than 5 m | 2017-06-15 |
20170165239 | USE OF BETA-CARBOLINE ALKALOID IN INHIBITING XANTHINE OXIDASE ACTIVITY - A method for inhibiting xanthine oxidase and for reducing uric acid levels using a beta-carboline alkaloid compound of formula (I), wherein R | 2017-06-15 |
20170165240 | NEW STRATEGIES FOR TREATING MELANOMA - The present invention relates to a p53-activating agent capable of transferring wild-type tumor protein p53 (p53) from an inactive conformation into an active conformation capable of inducing apoptosis, for use in the treatment of melanoma, wherein said p53-activating agent is administered simultaneously or sequentially with a BRAF-inhibiting agent capable of inhibiting activity of serine/threonine-protein kinase B-Raf (BRAF) comprising an activating mutation. | 2017-06-15 |
20170165241 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY - Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors and 15-PGDH activators described herein. | 2017-06-15 |
20170165242 | TREATMENT OF CANCERS WITH ACQUIRED RESISTANCE TO KIT INHIBITORS - The present invention provides compositions and methods for treating cancers which have acquired resistance to a KIT inhibitor by administering effective amounts of DAST. | 2017-06-15 |
20170165243 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS - This invention relates to novel pharmaceutical compositions comprising a solid dispersion of the compound of Formula I below, to processes for preparing these novel pharmaceutical compositions and to their use for treating hyper-proliferative disorders, such as cancer, either as a sole agent or in combination with other therapies. Formula I is as follows: | 2017-06-15 |
20170165244 | METHODS FOR TREATING AN IMPAIRMENT IN GAIT AND/OR BALANCE IN PATIENTS WITH MULTIPLE SCLEROSIS USING AN AMINOPYRIDINE - Disclosed herein is use of one or more aminopyridines in methods and compositions for treatment of impairments in gait or balance in patients with multiple sclerosis. | 2017-06-15 |
20170165245 | Sustained Release Aminopyridine Composition - A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases. | 2017-06-15 |
20170165246 | PHARMACEUTICAL COMBINATIONS COMPRISING A PI3K INHIBITOR FOR THE TREATMENT OF CANCER - A pharmaceutical combination comprising: (a) an alpha-isoform specific phosphatidylinositol-3-kinase inhibitor (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or any pharmaceutically acceptable salt thereof, (b) an mTOR inhibitor and (c) exemestane or any pharmaceutically acceptable salt thereof, particularly for use in the treatment or prevention of a proliferative disease; uses of such a combination in the preparation of a medicament for the treatment or prevention of a proliferative disease; pharmaceutical compositions of the combination of said therapeutic agents and methods of treating a proliferative disease in a subject comprising administering to said subject a therapeutically effective amount of such a combination. | 2017-06-15 |
20170165247 | CRYSTALLINE COMPOUNDS OF DABIGATRAN ETEXILATE - The present invention relates to new crystalline compounds of dabigatran etexilate, namely to crystalline compounds comprising mixtures of dabigatran etexilate and an acid. The invention also relates to processes for the preparation of the new crystalline compounds, pharmaceutical compositions comprising them and their use in therapy. | 2017-06-15 |
20170165248 | SOLID DOSAGE FORM COMPRISING PROTON PUMP INHIBITOR AND SUSPENSION MADE THEREOF - A solid, rapidly gelling oral pharmaceutical dosage form, as well as an aqueous formulation prepared thereof, comprising a) an acid sensitive proton pump inhibitor as active ingredient distributed in a multitude of enteric coated pellets, and b) a suspension modifying granulate. Furthermore, the invention relates to an improved process for the manufacture and the use of such formulation in medical treatment, including prevention of gastrointestinal disorders in humans. | 2017-06-15 |
20170165249 | COMPOSITIONS AND METHODS FOR TREATING DISEASES OF THE NAIL - Methods and compositions for treating disorders of the nail and nail bed. Such compositions contain a vehicle in which all components of the composition are dissolved, suspended, dispersed, or emulsified, a non-volatile solvent, a wetting agent, and a pharmaceutically active ingredient that is soluble in the non-volatile solvent and/or a mixture of the vehicle and the non-volatile solvent, and which composition is effective in treating a disorder of the nail or nail bed. | 2017-06-15 |
20170165250 | TREATMENT OF SCHIZOPHRENIA - Aspects of the invention relate generally to the treatment of schizophrenia and to monitoring for specific adverse reactions. | 2017-06-15 |
20170165251 | METHOD OF TREATING THERMOREGULATORY DYSFUNCTION WITH PAROXETINE - The present invention relates to a method for treating a patient suffering from a thermoregulatory dysfunction, especially hot flashes and flushes associated with hormonal changes due to naturally occurring menopause (whether male or female) or due to chemically or surgically induced menopause. The method is also applicable to treating the hot flashes, hot flushes, or night sweats associated with disease states that disrupt normal hormonal regulation of body temperature. | 2017-06-15 |
20170165252 | PROTEIN-ENRICHED THERAPEUTIC COMPOSITION - The present disclosure provides protein-enriched, nicotine-containing products, suitable for use as oral formulations. Products of the present disclosure typically include at least one nicotinic compound, at least one protein-enriched material (e.g., a tobacco-derived protein-enriched material), and at least one sugar alcohol. | 2017-06-15 |
20170165254 | TREATING FLAVIVIRUS INFECTIONS WITH AMODIAQUINE AND DERIVATIVES THEREOF - Methods of treating, preventing, and/or ameliorating a Flavivirus infection in a subject are disclosed. The methods comprise administering to the subject a therapeutically effective amount of a Flavivirus inhibitor. These methods are useful in treating, preventing, and/or ameliorating Flavivirus infections such as, for example, West Nile Virus, Dengue Virus, and Japanese Encephalitis Virus. | 2017-06-15 |
20170165255 | Oral Drug Delivery System - Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds. | 2017-06-15 |